Urological Cancer Drugs-China Market Status and Trend Report 2013-2023
Report Summary
Urological Cancer Drugs-China Market Status and Trend Report 2013-2023 offers a comprehensive analysis on Urological Cancer Drugs industry, standing on the readers? perspective, delivering detailed market data and penetrating insights. No matter the client is industry insider, potential entrant or investor, the report will provides useful data and information. Key questions answered by this report include:
Whole China and Regional Market Size of Urological Cancer Drugs 2013-2017, and development forecast 2018-2023
Main market players of Urological Cancer Drugs in China, with company and product introduction, position in the Urological Cancer Drugs market
Market status and development trend of Urological Cancer Drugs by types and applications
Cost and profit status of Urological Cancer Drugs, and marketing status
Market growth drivers and challenges
The report segments the China Urological Cancer Drugs market as:
China Urological Cancer Drugs Market: Regional Segment Analysis (Regional Consumption Volume, Consumption Volume, Revenue and Growth Rate 2013-2023):
North China
Northeast China
East China
Central & South China
Southwest China
Northwest China
China Urological Cancer Drugs Market: Product Type Segment Analysis (Consumption Volume, Average Price, Revenue, Market Share and Trend 2013-2023):
Xofigo (Radium Ra 223 Dichloride)
Jevtana (Cabazitaxel)
Inlyta (Axitinib)
Votrient (Pazopanib Hydrochloride)
Sutent (Sunitinib Malate)
Zytiga (Abiraterone Acetate)
Xtandi (Enzalutamide)
Opdivo (Nivolumab)
Provenge (Sipuleucel-T)
China Urological Cancer Drugs Market: Application Segment Analysis (Consumption Volume and Market Share 2013-2023; Downstream Customers and Market Analysis)
Prostate Cancer
Bladder Cancer
Kidney Cancer
Testicular Cancer
China Urological Cancer Drugs Market: Players Segment Analysis (Company and Product introduction, Urological Cancer Drugs Sales Volume, Revenue, Price and Gross Margin):
Novartis
Pfizer
Johnson & Johnson
AstraZeneca
Astellas
Bristol-Myers Squibb
Abbott Laboratories
Celgene Corporation
Dendreon Corporation
Ferring Pharmaceuticals
GlaxoSmithKline
Indevus Pharmaceuticals Inc
Ipsen
Roche Healthcare
Sanofi S.A.
Tolmar Inc
In a word, the report provides detailed statistics and analysis on the state of the industry; and is a valuable source of guidance and direction for companies and individuals interested in the market.
Urological Cancer Drugs-China Market Status and Trend Report 2013-2023 offers a comprehensive analysis on Urological Cancer Drugs industry, standing on the readers? perspective, delivering detailed market data and penetrating insights. No matter the client is industry insider, potential entrant or investor, the report will provides useful data and information. Key questions answered by this report include:
Whole China and Regional Market Size of Urological Cancer Drugs 2013-2017, and development forecast 2018-2023
Main market players of Urological Cancer Drugs in China, with company and product introduction, position in the Urological Cancer Drugs market
Market status and development trend of Urological Cancer Drugs by types and applications
Cost and profit status of Urological Cancer Drugs, and marketing status
Market growth drivers and challenges
The report segments the China Urological Cancer Drugs market as:
China Urological Cancer Drugs Market: Regional Segment Analysis (Regional Consumption Volume, Consumption Volume, Revenue and Growth Rate 2013-2023):
North China
Northeast China
East China
Central & South China
Southwest China
Northwest China
China Urological Cancer Drugs Market: Product Type Segment Analysis (Consumption Volume, Average Price, Revenue, Market Share and Trend 2013-2023):
Xofigo (Radium Ra 223 Dichloride)
Jevtana (Cabazitaxel)
Inlyta (Axitinib)
Votrient (Pazopanib Hydrochloride)
Sutent (Sunitinib Malate)
Zytiga (Abiraterone Acetate)
Xtandi (Enzalutamide)
Opdivo (Nivolumab)
Provenge (Sipuleucel-T)
China Urological Cancer Drugs Market: Application Segment Analysis (Consumption Volume and Market Share 2013-2023; Downstream Customers and Market Analysis)
Prostate Cancer
Bladder Cancer
Kidney Cancer
Testicular Cancer
China Urological Cancer Drugs Market: Players Segment Analysis (Company and Product introduction, Urological Cancer Drugs Sales Volume, Revenue, Price and Gross Margin):
Novartis
Pfizer
Johnson & Johnson
AstraZeneca
Astellas
Bristol-Myers Squibb
Abbott Laboratories
Celgene Corporation
Dendreon Corporation
Ferring Pharmaceuticals
GlaxoSmithKline
Indevus Pharmaceuticals Inc
Ipsen
Roche Healthcare
Sanofi S.A.
Tolmar Inc
In a word, the report provides detailed statistics and analysis on the state of the industry; and is a valuable source of guidance and direction for companies and individuals interested in the market.
CHAPTER 1 OVERVIEW OF UROLOGICAL CANCER DRUGS
1.1 Definition of Urological Cancer Drugs in This Report
1.2 Commercial Types of Urological Cancer Drugs
1.2.1 Xofigo (Radium Ra 223 Dichloride)
1.2.2 Jevtana (Cabazitaxel)
1.2.3 Inlyta (Axitinib)
1.2.4 Votrient (Pazopanib Hydrochloride)
1.2.5 Sutent (Sunitinib Malate)
1.2.6 Zytiga (Abiraterone Acetate)
1.2.7 Xtandi (Enzalutamide)
1.2.8 Opdivo (Nivolumab)
1.2.9 Provenge (Sipuleucel-T)
1.3 Downstream Application of Urological Cancer Drugs
1.3.1 Prostate Cancer
1.3.2 Bladder Cancer
1.3.3 Kidney Cancer
1.3.4 Testicular Cancer
1.4 Development History of Urological Cancer Drugs
1.5 Market Status and Trend of Urological Cancer Drugs 2013-2023
1.5.1 China Urological Cancer Drugs Market Status and Trend 2013-2023
1.5.2 Regional Urological Cancer Drugs Market Status and Trend 2013-2023
CHAPTER 2 CHINA MARKET STATUS AND FORECAST BY REGIONS
2.1 Market Status of Urological Cancer Drugs in China 2013-2017
2.2 Consumption Market of Urological Cancer Drugs in China by Regions
2.2.1 Consumption Volume of Urological Cancer Drugs in China by Regions
2.2.2 Revenue of Urological Cancer Drugs in China by Regions
2.3 Market Analysis of Urological Cancer Drugs in China by Regions
2.3.1 Market Analysis of Urological Cancer Drugs in North China 2013-2017
2.3.2 Market Analysis of Urological Cancer Drugs in Northeast China 2013-2017
2.3.3 Market Analysis of Urological Cancer Drugs in East China 2013-2017
2.3.4 Market Analysis of Urological Cancer Drugs in Central & South China 2013-2017
2.3.5 Market Analysis of Urological Cancer Drugs in Southwest China 2013-2017
2.3.6 Market Analysis of Urological Cancer Drugs in Northwest China 2013-2017
2.4 Market Development Forecast of Urological Cancer Drugs in China 2018-2023
2.4.1 Market Development Forecast of Urological Cancer Drugs in China 2018-2023
2.4.2 Market Development Forecast of Urological Cancer Drugs by Regions 2018-2023
CHAPTER 3 CHINA MARKET STATUS AND FORECAST BY TYPES
3.1 Whole China Market Status by Types
3.1.1 Consumption Volume of Urological Cancer Drugs in China by Types
3.1.2 Revenue of Urological Cancer Drugs in China by Types
3.2 China Market Status by Types in Major Countries
3.2.1 Market Status by Types in North China
3.2.2 Market Status by Types in Northeast China
3.2.3 Market Status by Types in East China
3.2.4 Market Status by Types in Central & South China
3.2.5 Market Status by Types in Southwest China
3.2.6 Market Status by Types in Northwest China
3.3 Market Forecast of Urological Cancer Drugs in China by Types
CHAPTER 4 CHINA MARKET STATUS AND FORECAST BY DOWNSTREAM INDUSTRY
4.1 Demand Volume of Urological Cancer Drugs in China by Downstream Industry
4.2 Demand Volume of Urological Cancer Drugs by Downstream Industry in Major Countries
4.2.1 Demand Volume of Urological Cancer Drugs by Downstream Industry in North China
4.2.2 Demand Volume of Urological Cancer Drugs by Downstream Industry in Northeast China
4.2.3 Demand Volume of Urological Cancer Drugs by Downstream Industry in East China
4.2.4 Demand Volume of Urological Cancer Drugs by Downstream Industry in Central & South China
4.2.5 Demand Volume of Urological Cancer Drugs by Downstream Industry in Southwest China
4.2.6 Demand Volume of Urological Cancer Drugs by Downstream Industry in Northwest China
4.3 Market Forecast of Urological Cancer Drugs in China by Downstream Industry
CHAPTER 5 MARKET DRIVING FACTOR ANALYSIS OF UROLOGICAL CANCER DRUGS
5.1 China Economy Situation and Trend Overview
5.2 Urological Cancer Drugs Downstream Industry Situation and Trend Overview
CHAPTER 6 UROLOGICAL CANCER DRUGS MARKET COMPETITION STATUS BY MAJOR PLAYERS IN CHINA
6.1 Sales Volume of Urological Cancer Drugs in China by Major Players
6.2 Revenue of Urological Cancer Drugs in China by Major Players
6.3 Basic Information of Urological Cancer Drugs by Major Players
6.3.1 Headquarters Location and Established Time of Urological Cancer Drugs Major Players
6.3.2 Employees and Revenue Level of Urological Cancer Drugs Major Players
6.4 Market Competition News and Trend
6.4.1 Merger, Consolidation or Acquisition News
6.4.2 Investment or Disinvestment News
6.4.3 New Product Development and Launch
CHAPTER 7 UROLOGICAL CANCER DRUGS MAJOR MANUFACTURERS INTRODUCTION AND MARKET DATA
7.1 Novartis
7.1.1 Company profile
7.1.2 Representative Urological Cancer Drugs Product
7.1.3 Urological Cancer Drugs Sales, Revenue, Price and Gross Margin of Novartis
7.2 Pfizer
7.2.1 Company profile
7.2.2 Representative Urological Cancer Drugs Product
7.2.3 Urological Cancer Drugs Sales, Revenue, Price and Gross Margin of Pfizer
7.3 Johnson & Johnson
7.3.1 Company profile
7.3.2 Representative Urological Cancer Drugs Product
7.3.3 Urological Cancer Drugs Sales, Revenue, Price and Gross Margin of Johnson & Johnson
7.4 AstraZeneca
7.4.1 Company profile
7.4.2 Representative Urological Cancer Drugs Product
7.4.3 Urological Cancer Drugs Sales, Revenue, Price and Gross Margin of AstraZeneca
7.5 Astellas
7.5.1 Company profile
7.5.2 Representative Urological Cancer Drugs Product
7.5.3 Urological Cancer Drugs Sales, Revenue, Price and Gross Margin of Astellas
7.6 Bristol-Myers Squibb
7.6.1 Company profile
7.6.2 Representative Urological Cancer Drugs Product
7.6.3 Urological Cancer Drugs Sales, Revenue, Price and Gross Margin of Bristol-Myers Squibb
7.7 Abbott Laboratories
7.7.1 Company profile
7.7.2 Representative Urological Cancer Drugs Product
7.7.3 Urological Cancer Drugs Sales, Revenue, Price and Gross Margin of Abbott Laboratories
7.8 Celgene Corporation
7.8.1 Company profile
7.8.2 Representative Urological Cancer Drugs Product
7.8.3 Urological Cancer Drugs Sales, Revenue, Price and Gross Margin of Celgene Corporation
7.9 Dendreon Corporation
7.9.1 Company profile
7.9.2 Representative Urological Cancer Drugs Product
7.9.3 Urological Cancer Drugs Sales, Revenue, Price and Gross Margin of Dendreon Corporation
7.10 Ferring Pharmaceuticals
7.10.1 Company profile
7.10.2 Representative Urological Cancer Drugs Product
7.10.3 Urological Cancer Drugs Sales, Revenue, Price and Gross Margin of Ferring Pharmaceuticals
7.11 GlaxoSmithKline
7.11.1 Company profile
7.11.2 Representative Urological Cancer Drugs Product
7.11.3 Urological Cancer Drugs Sales, Revenue, Price and Gross Margin of GlaxoSmithKline
7.12 Indevus Pharmaceuticals Inc
7.12.1 Company profile
7.12.2 Representative Urological Cancer Drugs Product
7.12.3 Urological Cancer Drugs Sales, Revenue, Price and Gross Margin of Indevus Pharmaceuticals Inc
7.13 Ipsen
7.13.1 Company profile
7.13.2 Representative Urological Cancer Drugs Product
7.13.3 Urological Cancer Drugs Sales, Revenue, Price and Gross Margin of Ipsen
7.14 Roche Healthcare
7.14.1 Company profile
7.14.2 Representative Urological Cancer Drugs Product
7.14.3 Urological Cancer Drugs Sales, Revenue, Price and Gross Margin of Roche Healthcare
7.15 Sanofi S.A.
7.15.1 Company profile
7.15.2 Representative Urological Cancer Drugs Product
7.15.3 Urological Cancer Drugs Sales, Revenue, Price and Gross Margin of Sanofi S.A.
7.16 Tolmar Inc
CHAPTER 8 UPSTREAM AND DOWNSTREAM MARKET ANALYSIS OF UROLOGICAL CANCER DRUGS
8.1 Industry Chain of Urological Cancer Drugs
8.2 Upstream Market and Representative Companies Analysis
8.3 Downstream Market and Representative Companies Analysis
CHAPTER 9 COST AND GROSS MARGIN ANALYSIS OF UROLOGICAL CANCER DRUGS
9.1 Cost Structure Analysis of Urological Cancer Drugs
9.2 Raw Materials Cost Analysis of Urological Cancer Drugs
9.3 Labor Cost Analysis of Urological Cancer Drugs
9.4 Manufacturing Expenses Analysis of Urological Cancer Drugs
CHAPTER 10 MARKETING STATUS ANALYSIS OF UROLOGICAL CANCER DRUGS
10.1 Marketing Channel
10.1.1 Direct Marketing
10.1.2 Indirect Marketing
10.1.3 Marketing Channel Development Trend
10.2 Market Positioning
10.2.1 Pricing Strategy
10.2.2 Brand Strategy
10.2.3 Target Client
10.3 Distributors/Traders List
CHAPTER 11 REPORT CONCLUSION
CHAPTER 12 RESEARCH METHODOLOGY AND REFERENCE
12.1 Methodology/Research Approach
12.1.1 Research Programs/Design
12.1.2 Market Size Estimation
12.1.3 Market Breakdown and Data Triangulation
12.2 Data Source
12.2.1 Secondary Sources
12.2.2 Primary Sources
12.3 Reference
1.1 Definition of Urological Cancer Drugs in This Report
1.2 Commercial Types of Urological Cancer Drugs
1.2.1 Xofigo (Radium Ra 223 Dichloride)
1.2.2 Jevtana (Cabazitaxel)
1.2.3 Inlyta (Axitinib)
1.2.4 Votrient (Pazopanib Hydrochloride)
1.2.5 Sutent (Sunitinib Malate)
1.2.6 Zytiga (Abiraterone Acetate)
1.2.7 Xtandi (Enzalutamide)
1.2.8 Opdivo (Nivolumab)
1.2.9 Provenge (Sipuleucel-T)
1.3 Downstream Application of Urological Cancer Drugs
1.3.1 Prostate Cancer
1.3.2 Bladder Cancer
1.3.3 Kidney Cancer
1.3.4 Testicular Cancer
1.4 Development History of Urological Cancer Drugs
1.5 Market Status and Trend of Urological Cancer Drugs 2013-2023
1.5.1 China Urological Cancer Drugs Market Status and Trend 2013-2023
1.5.2 Regional Urological Cancer Drugs Market Status and Trend 2013-2023
CHAPTER 2 CHINA MARKET STATUS AND FORECAST BY REGIONS
2.1 Market Status of Urological Cancer Drugs in China 2013-2017
2.2 Consumption Market of Urological Cancer Drugs in China by Regions
2.2.1 Consumption Volume of Urological Cancer Drugs in China by Regions
2.2.2 Revenue of Urological Cancer Drugs in China by Regions
2.3 Market Analysis of Urological Cancer Drugs in China by Regions
2.3.1 Market Analysis of Urological Cancer Drugs in North China 2013-2017
2.3.2 Market Analysis of Urological Cancer Drugs in Northeast China 2013-2017
2.3.3 Market Analysis of Urological Cancer Drugs in East China 2013-2017
2.3.4 Market Analysis of Urological Cancer Drugs in Central & South China 2013-2017
2.3.5 Market Analysis of Urological Cancer Drugs in Southwest China 2013-2017
2.3.6 Market Analysis of Urological Cancer Drugs in Northwest China 2013-2017
2.4 Market Development Forecast of Urological Cancer Drugs in China 2018-2023
2.4.1 Market Development Forecast of Urological Cancer Drugs in China 2018-2023
2.4.2 Market Development Forecast of Urological Cancer Drugs by Regions 2018-2023
CHAPTER 3 CHINA MARKET STATUS AND FORECAST BY TYPES
3.1 Whole China Market Status by Types
3.1.1 Consumption Volume of Urological Cancer Drugs in China by Types
3.1.2 Revenue of Urological Cancer Drugs in China by Types
3.2 China Market Status by Types in Major Countries
3.2.1 Market Status by Types in North China
3.2.2 Market Status by Types in Northeast China
3.2.3 Market Status by Types in East China
3.2.4 Market Status by Types in Central & South China
3.2.5 Market Status by Types in Southwest China
3.2.6 Market Status by Types in Northwest China
3.3 Market Forecast of Urological Cancer Drugs in China by Types
CHAPTER 4 CHINA MARKET STATUS AND FORECAST BY DOWNSTREAM INDUSTRY
4.1 Demand Volume of Urological Cancer Drugs in China by Downstream Industry
4.2 Demand Volume of Urological Cancer Drugs by Downstream Industry in Major Countries
4.2.1 Demand Volume of Urological Cancer Drugs by Downstream Industry in North China
4.2.2 Demand Volume of Urological Cancer Drugs by Downstream Industry in Northeast China
4.2.3 Demand Volume of Urological Cancer Drugs by Downstream Industry in East China
4.2.4 Demand Volume of Urological Cancer Drugs by Downstream Industry in Central & South China
4.2.5 Demand Volume of Urological Cancer Drugs by Downstream Industry in Southwest China
4.2.6 Demand Volume of Urological Cancer Drugs by Downstream Industry in Northwest China
4.3 Market Forecast of Urological Cancer Drugs in China by Downstream Industry
CHAPTER 5 MARKET DRIVING FACTOR ANALYSIS OF UROLOGICAL CANCER DRUGS
5.1 China Economy Situation and Trend Overview
5.2 Urological Cancer Drugs Downstream Industry Situation and Trend Overview
CHAPTER 6 UROLOGICAL CANCER DRUGS MARKET COMPETITION STATUS BY MAJOR PLAYERS IN CHINA
6.1 Sales Volume of Urological Cancer Drugs in China by Major Players
6.2 Revenue of Urological Cancer Drugs in China by Major Players
6.3 Basic Information of Urological Cancer Drugs by Major Players
6.3.1 Headquarters Location and Established Time of Urological Cancer Drugs Major Players
6.3.2 Employees and Revenue Level of Urological Cancer Drugs Major Players
6.4 Market Competition News and Trend
6.4.1 Merger, Consolidation or Acquisition News
6.4.2 Investment or Disinvestment News
6.4.3 New Product Development and Launch
CHAPTER 7 UROLOGICAL CANCER DRUGS MAJOR MANUFACTURERS INTRODUCTION AND MARKET DATA
7.1 Novartis
7.1.1 Company profile
7.1.2 Representative Urological Cancer Drugs Product
7.1.3 Urological Cancer Drugs Sales, Revenue, Price and Gross Margin of Novartis
7.2 Pfizer
7.2.1 Company profile
7.2.2 Representative Urological Cancer Drugs Product
7.2.3 Urological Cancer Drugs Sales, Revenue, Price and Gross Margin of Pfizer
7.3 Johnson & Johnson
7.3.1 Company profile
7.3.2 Representative Urological Cancer Drugs Product
7.3.3 Urological Cancer Drugs Sales, Revenue, Price and Gross Margin of Johnson & Johnson
7.4 AstraZeneca
7.4.1 Company profile
7.4.2 Representative Urological Cancer Drugs Product
7.4.3 Urological Cancer Drugs Sales, Revenue, Price and Gross Margin of AstraZeneca
7.5 Astellas
7.5.1 Company profile
7.5.2 Representative Urological Cancer Drugs Product
7.5.3 Urological Cancer Drugs Sales, Revenue, Price and Gross Margin of Astellas
7.6 Bristol-Myers Squibb
7.6.1 Company profile
7.6.2 Representative Urological Cancer Drugs Product
7.6.3 Urological Cancer Drugs Sales, Revenue, Price and Gross Margin of Bristol-Myers Squibb
7.7 Abbott Laboratories
7.7.1 Company profile
7.7.2 Representative Urological Cancer Drugs Product
7.7.3 Urological Cancer Drugs Sales, Revenue, Price and Gross Margin of Abbott Laboratories
7.8 Celgene Corporation
7.8.1 Company profile
7.8.2 Representative Urological Cancer Drugs Product
7.8.3 Urological Cancer Drugs Sales, Revenue, Price and Gross Margin of Celgene Corporation
7.9 Dendreon Corporation
7.9.1 Company profile
7.9.2 Representative Urological Cancer Drugs Product
7.9.3 Urological Cancer Drugs Sales, Revenue, Price and Gross Margin of Dendreon Corporation
7.10 Ferring Pharmaceuticals
7.10.1 Company profile
7.10.2 Representative Urological Cancer Drugs Product
7.10.3 Urological Cancer Drugs Sales, Revenue, Price and Gross Margin of Ferring Pharmaceuticals
7.11 GlaxoSmithKline
7.11.1 Company profile
7.11.2 Representative Urological Cancer Drugs Product
7.11.3 Urological Cancer Drugs Sales, Revenue, Price and Gross Margin of GlaxoSmithKline
7.12 Indevus Pharmaceuticals Inc
7.12.1 Company profile
7.12.2 Representative Urological Cancer Drugs Product
7.12.3 Urological Cancer Drugs Sales, Revenue, Price and Gross Margin of Indevus Pharmaceuticals Inc
7.13 Ipsen
7.13.1 Company profile
7.13.2 Representative Urological Cancer Drugs Product
7.13.3 Urological Cancer Drugs Sales, Revenue, Price and Gross Margin of Ipsen
7.14 Roche Healthcare
7.14.1 Company profile
7.14.2 Representative Urological Cancer Drugs Product
7.14.3 Urological Cancer Drugs Sales, Revenue, Price and Gross Margin of Roche Healthcare
7.15 Sanofi S.A.
7.15.1 Company profile
7.15.2 Representative Urological Cancer Drugs Product
7.15.3 Urological Cancer Drugs Sales, Revenue, Price and Gross Margin of Sanofi S.A.
7.16 Tolmar Inc
CHAPTER 8 UPSTREAM AND DOWNSTREAM MARKET ANALYSIS OF UROLOGICAL CANCER DRUGS
8.1 Industry Chain of Urological Cancer Drugs
8.2 Upstream Market and Representative Companies Analysis
8.3 Downstream Market and Representative Companies Analysis
CHAPTER 9 COST AND GROSS MARGIN ANALYSIS OF UROLOGICAL CANCER DRUGS
9.1 Cost Structure Analysis of Urological Cancer Drugs
9.2 Raw Materials Cost Analysis of Urological Cancer Drugs
9.3 Labor Cost Analysis of Urological Cancer Drugs
9.4 Manufacturing Expenses Analysis of Urological Cancer Drugs
CHAPTER 10 MARKETING STATUS ANALYSIS OF UROLOGICAL CANCER DRUGS
10.1 Marketing Channel
10.1.1 Direct Marketing
10.1.2 Indirect Marketing
10.1.3 Marketing Channel Development Trend
10.2 Market Positioning
10.2.1 Pricing Strategy
10.2.2 Brand Strategy
10.2.3 Target Client
10.3 Distributors/Traders List
CHAPTER 11 REPORT CONCLUSION
CHAPTER 12 RESEARCH METHODOLOGY AND REFERENCE
12.1 Methodology/Research Approach
12.1.1 Research Programs/Design
12.1.2 Market Size Estimation
12.1.3 Market Breakdown and Data Triangulation
12.2 Data Source
12.2.1 Secondary Sources
12.2.2 Primary Sources
12.3 Reference
